Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Mass Spec Predicts Improved Response to Anti-HER2 Therapy in Breast Cancer

Published: Monday, July 07, 2014
Last Updated: Monday, July 07, 2014
Bookmark and Share
Immunohistochemistry is the standard technique for detecting HER2 protein expression, it does not provide absolute quantification of this receptor and is prone to false-positives.

A collaborative study between OncoPlex Diagnostics, Vall d´Hebron Institute of Oncology (VHIO), and Memorial Sloan Kettering Cancer Center, with support from the BBVA Foundation, defined for the first time a quantitative HER2 protein level measured by mass spectrometry is associated with longer disease free and overall survival in patients receiving anti-HER2 treatment.   Results of the study were presented during the ASCO 2014 Annual Meeting by Dr. Paolo Nuciforo, Principal Investigator of VHIO´s Molecular Oncology Group. 

While immunohistochemistry (IHC) is the standard technique for detecting HER2 protein expression, it does not provide absolute quantification of this receptor and is prone to false-positives. Many patients who are classified by IHC as HER2-positive actually express low levels of the receptor which dramatically reduces efficacy of anti-HER2 therapy. 

OncoPlex Diagnostics uses the patented Liquid Tissue® process to solubilize formalin-fixed, paraffin-embedded (FFPE) tissue for precise protein quantitation by mass spectrometry analysis.  The study analyzed tissue from 60 breast cancer patients previously classified as IHC 3+ and treated with anti-HER2 therapy.  The research revealed high variability in HER2 expression within the patient population that had been homogenously classified as 3+ by IHC. Patients with HER2 protein levels greater than or equal to 2758.75 amol/ug, as measured by mass spectrometry, correlated with greater clinical benefit including prolonged survival rates.  The ASCO poster presentation is available at OncoPlex Dx HER2 ASCO2014 Collaboration.

"This study provides evidence that quantitative measurement by mass spectrometry of a tumor-driving protein such as HER2 correlates with the clinical benefit associated with HER2 targeted therapy," stated Dr. Jedd Levine, Chief Medical Officer for OncoPlex Diagnostics. The primary investigator, Dr. Nucifiro, explains, "If future (ongoing) studies enrolling a greater number of patients confirm these results, this would represent an important game-changer in how we currently determine HER2 expression levels as well as provide oncologists with further insight to better tailor anti-HER2-based therapies according to HER2 protein levels."


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
'Fountain of Youth' Protein Points to Possible Human Health Benefit
Patients with higher blood levels of growth factor have lower risk of cardiovascular problems.
Signature of Microbiomes Linked to Schizophrenia
Studying microbiomes in throat may help identify causes and treatments of brain disorder.
Imaging Software Could Speed Breast Cancer Diagnosis
Technology could improve access to diagnostic services in developing countries.
Data Mining DNA For Polycystic Ovary Syndrome Genes
A new Northwestern Medicine genome-wide association study of PCOS – the first of its kind to focus on women of European ancestry – has provided important new insights into the underlying biology of the disorder.
Algorithm Interprets Breathing Difficulties to Aid in Medical Care
Researchers from North Carolina State University have developed an efficient algorithm that can interpret the wheezing of patients with breathing difficulties to give medical providers information about what’s happening in the lungs.
Researchers Develop qPCR Prognosis Test for NSCLC Patients
A nine-gene molecular prognostic index (MPI) for patients with early-stage non-small cell lung cancer (NSCLC) was able to provide accurate survival stratification and could potentially inform the use of adjuvant therapy in patients struggling with the disease.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!